Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

News & Events

2016, Past Events

World Immunotherapy Congress 2016

Nov 1, 2016

Philogen S.p.A. announces participation in the “World Immunotherapy Congress 2016”, 14 – 16 November 2016, Basel, Switzerland

PHILOGEN S.P.A. ANNOUNCES PARTICIPATIO IN THE “WORLD IMMUNOTHERAPY CONGRESS 2016”, 14 – 16 NOVEMBER 2016, BASEL, SWITZERLAND

Last News & Events

Oct 2017 19

Philogen announces the authorisation of a clinical trial with PHC-102 for the imaging of renal cell carcinoma.

Oct 2017 12

Philogen announces authorization from FDA of a pivotal registration trial in USA for the treatment of resectable melanoma

  • « Previous
  • 1
  • …
  • 94
  • 95
  • 96
  • 97
  • 98
  • …
  • 104
  • Next »

Privacy Policy / Cookie Policy

  Contacts

  • Follow
  • Follow

Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it